Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.32 |
| ▸ | TACR2 | P21452 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13437775 | 0.80 | HRH1 (0.33) | HRH1KCNH2 | |
| SCHEMBL4550212 | 0.78 | DRD2 (0.42) | SMN1; SMN2 | |
| SCHEMBL469147 | 0.77 | CARM1 (0.47) | HRH1KCNH2 | |
| SCHEMBL18173367 | 0.75 | HRH1 (0.35) | SMN1; SMN2ALOX15HRH1KCNH2 | |
| SCHEMBL13437773 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2ALOX15KCNH2MAPT | |
| SCHEMBL13437776 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2ALOX15HRH1KCNH2MAPT | |
| SCHEMBL20541135 | 0.74 | SLC18A3 (0.42) | ALOX15HRH1KCNH2LTA4H | |
| SCHEMBL4550204 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTLTA4H | |
| SCHEMBL7884661 | 0.74 | KCNH2 (0.34) | SMN1; SMN2ALOX15HRH1KCNH2MAPT | |
| SCHEMBL441449 | 0.74 | HRH1 (0.34) | SMN1; SMN2ALOX15HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683077-B2 | Piperidine derivative | AJINOMOTO CO., INC. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20070021460-A1 | Novel piperidine derivative | AJINOMOTO CO., INC. (JP) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021460-A1 | Novel piperidine derivative | HTR7, TPH1, HTR5A | SMN1; SMN2 3936/4885ALOX15 355/4885HRH1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.